JPMorgan analyst Anupam Rama raised the firm’s price target on BridgeBio (BBIO) to $77 from $76 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $100 from $55 at Goldman Sachs
- BridgeBio Pharma’s Earnings Call Highlights Success and Challenges
- BridgeBio price target raised to $80 from $66 at Truist
- BridgeBio price target raised to $95 from $60 at TD Cowen
- BridgeBio price target raised to $81 from $73 at Oppenheimer